NASDAQ:CNCE Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free CNCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.37▼$8.3750-Day Range$8.33▼$8.4052-Week Range$2.66▼$8.55VolumeN/AAverage Volume2.97 million shsMarket Capitalization$401.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Concert Pharmaceuticals alerts: Email Address Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About Concert Pharmaceuticals Stock (NASDAQ:CNCE)Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Read More Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. CNCE Stock News HeadlinesApril 7, 2024 | nytimes.comThe Best Bag to Bring to a Concert Is Actually a Running BeltApril 1, 2024 | au.news.yahoo.comTeresa Giudice and Her Lookalike Daughters Glam Up for Nicki Minaj Concert: ‘New Jersey Takes Gag City’April 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 30, 2024 | msn.comVideo: Pharma boss apologises after pill linked to five deaths and over 100 hospitalisationsOctober 28, 2023 | nypost.comNFL pushed networks to air Taylor Swift concert film promos — for freeOctober 2, 2023 | msn.comBeyoncé 'Renaissance' Movie Tickets and How To See Concert Film in TheatersSeptember 15, 2023 | usatoday.comTaylor Swift 'overjoyed' to release Eras Tour concert movie: How to watchSeptember 12, 2023 | usatoday.comBruce Springsteen forced to postpone Philadelphia concerts with E Street Band due to illnessApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."August 7, 2023 | usatoday.comMiranda Lambert scolds fans for taking selfies during her concert: 'I don't like it'August 6, 2023 | usatoday.comThe worst people at concerts, from self-involved selfie takers to nonstop filmersJuly 25, 2023 | bbc.co.ukHighlights from King Charles III Coronation concertJuly 17, 2023 | usatoday.comFan throws bag of ashes at Pink during tour concertJuly 4, 2023 | ca.style.yahoo.comBirds Papaya stuns fans in Shania Twain-inspired outfit for concertMay 7, 2023 | bbc.comHow to watch the Coronation and Coronation Concert on BBC TV and iPlayer and listen on radio and BBC SoundsMay 4, 2023 | bbc.co.ukTicket ballot for the Coronation ConcertMarch 26, 2023 | msn.comWho is Florence Price? Find out at a free Philadelphia Orchestra concert SaturdayFebruary 15, 2023 | finance.yahoo.comConcert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia AreataFebruary 6, 2023 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Concert Pharma (CNCE)January 30, 2023 | benzinga.comMoore Kuehn Encourages KERN, CNCE, AQUA and ANGN Investors to Contact Law FirmJanuary 23, 2023 | finance.yahoo.comConcert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout OfferJanuary 22, 2023 | msn.com5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaJanuary 20, 2023 | finance.yahoo.comWhy Concert Pharmaceuticals Stock Rocketed Higher This WeekJanuary 20, 2023 | marketwatch.comCNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to ShareholdersJanuary 19, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Concert Pharmaceuticals, Inc. (CNCE)January 19, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun PharmaJanuary 19, 2023 | marketwatch.comConcert Pharmaceuticals Shares Rally on Takeover by Sun >CNCESee More Headlines Receive CNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNCE CUSIPN/A CIK1367920 Webwww.concertpharma.com Phone(781) 860-0045Fax302-636-5454Employees64Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,050,000.00 Net MarginsN/A Pretax Margin-300,735.69% Return on Equity-109.43% Return on Assets-76.65% Debt Debt-to-Equity RatioN/A Current Ratio9.03 Quick Ratio9.03 Sales & Book Value Annual Sales$32.58 million Price / Sales12.32 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book2.58Miscellaneous Outstanding Shares47,940,000Free Float42,507,000Market Cap$401.26 million OptionableOptionable Beta0.52 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesRoger D. TungPresident, Chief Executive Officer & DirectorNancy StuartChief Operating OfficerMarc A. BeckerChief Financial & Accounting OfficerMitch K. GoldenbergVP-Information Technology & InfrastructureVirginia BramanVice President-Clinical DevelopmentKey CompetitorsNeurogeneNASDAQ:NGNEAnnexonNASDAQ:ANNXCorbus PharmaceuticalsNASDAQ:CRBPEsperion TherapeuticsNASDAQ:ESPRBiomea FusionNASDAQ:BMEAView All Competitors CNCE Stock Analysis - Frequently Asked Questions How were Concert Pharmaceuticals' earnings last quarter? Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.25 million. During the same period last year, the business posted ($0.60) earnings per share. What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO? 1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Concert Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC). This page (NASDAQ:CNCE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Concert Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
